Eli Lilly Q4: Don't Miss Out On 2025 Gains, There's Limited Space Left
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
BioSpace12h
After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build-Out Is ‘Over Our Skis’
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
Hosted on MSN12h
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars
Shares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...
Is the promise of more affordable weight loss drugs too good to be true? Compounded semaglutide, explained.
Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.
WPEC West Palm Beach on MSN6h
The battle over anti-obesity medications
The new class of anti-obesity medications has become some of the most sought-after prescription drugs in history. According ...
thedailyupside23h
Weight-Loss Giants Have Investors Back on Their Side
It can be hard to sate investors’ appetites, but if there’s two companies who should know how to do it, it’s these two.
Therapy dog brings joy to medical center patients, staff
Kismet, an English Springer Spaniel, and her owner Stacey Yeoman have been bringing joy to patients and staff at Novant Health Mint Hill Medical Center for the past two months as a therapy dog team.